(AOF) – Nicox announces a cash position of 9.1 million euros as of March 31, 2024: its cash horizon extends until November 2024. The international company specializing in ophthalmology specifies that its turnover reached 4 .4 million euros for the first quarter of 2024 and 6.9 million for the year 2023. Nicox SA’s net loss for the entire year 2023 amounted to 20.9 million euros, compared to 31.3 million euros for the whole of 2022. The difference mainly corresponds to the variation in the provision for depreciation of the securities of its American subsidiary.
“Nicox has made good progress in 2023 with initial results from the Phase 3 Denali study expected in the second half of 2025,” said Gavin Spencer, Chief Executive Officer of Nicox. “We are focused on the development of NCX 470 and advancing the Denali study which is expected to confirm the profile of NCX 470 in glaucoma and open additional strategic options and commercialization pathways beyond our existing partnerships “.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.